[go: up one dir, main page]

DK0667901T4 - Hidtil ukendt cytokin - Google Patents

Hidtil ukendt cytokin

Info

Publication number
DK0667901T4
DK0667901T4 DK92925017T DK92925017T DK0667901T4 DK 0667901 T4 DK0667901 T4 DK 0667901T4 DK 92925017 T DK92925017 T DK 92925017T DK 92925017 T DK92925017 T DK 92925017T DK 0667901 T4 DK0667901 T4 DK 0667901T4
Authority
DK
Denmark
Prior art keywords
hitherto unknown
unknown cytokine
cytokine
hitherto
immunogen
Prior art date
Application number
DK92925017T
Other languages
Danish (da)
English (en)
Other versions
DK0667901T3 (da
Inventor
Richard J Armitage
William C Fanslow
Melanie K Spriggs
Srinivasan Subhashini
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0667901(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DK0667901T3 publication Critical patent/DK0667901T3/da
Application granted granted Critical
Publication of DK0667901T4 publication Critical patent/DK0667901T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK92925017T 1991-10-25 1992-10-23 Hidtil ukendt cytokin DK0667901T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US80572391A 1991-12-05 1991-12-05
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine

Publications (2)

Publication Number Publication Date
DK0667901T3 DK0667901T3 (da) 2004-12-27
DK0667901T4 true DK0667901T4 (da) 2008-11-10

Family

ID=27120174

Family Applications (3)

Application Number Title Priority Date Filing Date
DK98113461T DK0897983T3 (da) 1991-10-25 1992-10-23 Antistoffer mod CD40-L
DK92925017T DK0667901T4 (da) 1991-10-25 1992-10-23 Hidtil ukendt cytokin
DK97117514T DK0822199T3 (da) 1991-10-25 1992-10-23 N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK98113461T DK0897983T3 (da) 1991-10-25 1992-10-23 Antistoffer mod CD40-L

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97117514T DK0822199T3 (da) 1991-10-25 1992-10-23 N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf

Country Status (12)

Country Link
EP (2) EP0667901B2 (de)
JP (2) JP3308534B2 (de)
KR (1) KR100283541B1 (de)
AT (2) ATE239790T1 (de)
AU (1) AU661360B2 (de)
CA (2) CA2312667C (de)
DE (2) DE69233051T2 (de)
DK (3) DK0897983T3 (de)
ES (2) ES2227513T5 (de)
FI (2) FI116850B (de)
NO (2) NO317625B1 (de)
WO (1) WO1993008207A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
EP0612529B1 (de) * 1993-01-22 2000-04-05 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutisches Agens für NIDDM
ES2211876T3 (es) * 1993-01-22 2004-07-16 Immunex Corporation Deteccion y tratamiento de mutaciones en un gel del ligando de cd40.
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
NZ549136A (en) * 1993-09-02 2008-02-29 Dartmouth College Products for inducing antigen-specific T cell tolerance
DK0742721T3 (da) * 1993-09-02 1999-11-01 Dartmouth College Fremgangsmåder til forlænget suppression af humoral immunitet
KR100398819B1 (ko) 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
WO1995014487A1 (en) * 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
CA2179196A1 (en) * 1993-12-23 1995-06-29 Richard J. Armitage Method of preventing or treating disease characterized by neoplastic cells expressing cd40
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
MX9605088A (es) 1994-04-28 1997-08-30 Boehringer Ingelheim Pharma Metodos para proliferar y diferenciar celulas b y sus usos.
ES2179187T3 (es) * 1995-03-01 2003-01-16 Immunex Corp Oriteuba qye se yba a cd40 para estimular una respuesta inmune.
AU2556195A (en) 1995-03-13 1996-10-02 Regents Of The University Of Michigan, The CD40 binding compositions and methods of using same
MX9709447A (es) * 1995-06-07 1998-02-28 Immunex Corp Nueva muteina cd4ol.
CA2224812A1 (en) * 1995-06-22 1997-01-09 Biogen, Inc. Crystals of fragments of cd40 ligand and their use
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EP0910474B1 (de) * 1996-06-14 2004-03-24 University of Washington Absorbtionsverbessertes differentielles extraktionsverfahren
JP2002514047A (ja) * 1996-07-10 2002-05-14 イミュネックス・コーポレーション 樹状細胞を活性化する方法
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
DE951551T1 (de) * 1996-12-23 2000-09-14 Immunex Corp., Seattle Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
ATE412746T1 (de) 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
HK1042114B (zh) * 1998-10-23 2006-09-29 Amgen K-A, Inc. 与mp1受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (de) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vektoren, die Gene enthalten, die für CD40 und/oder CD40L kodieren die unter der Kontrolle von einer Cytokin-induzierbaren Promotorsequenz sind. Dieser Promotor stammt von einem menschlischen akutphasen-Serumamyloid-A-Gen. Verfahren zur Herstellung derselben und Verwendung davon
WO2000063395A1 (en) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
AU6934600A (en) * 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CN1441675A (zh) 2000-05-12 2003-09-10 贝斯以色列护理医疗中心有限公司 免疫抑制组合物及方法
PT1326896E (pt) 2000-10-02 2011-03-03 Novartis Vaccines & Diagnostic Anticorpos humanos anti-cd40
WO2002036769A2 (en) * 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1409016B9 (de) 2001-06-26 2020-10-28 Amgen Fremont Inc. Antikörper gegen opgl
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
EP1414483A1 (de) * 2001-07-31 2004-05-06 Serono Genetics Institute S.A. Agonisten und antagonisten von moxifin zur behandlung von stoffwechselerkrankungen
JP4266825B2 (ja) 2001-09-20 2009-05-20 イミユネツクス・コーポレイシヨン ヘテロマーポリペプチドを発現する細胞の選択
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
ATE553185T1 (de) 2003-02-14 2012-04-15 Biogen Idec Inc Expressionskassette und vektor zur transienten oder stabilen expression exogener moleküle
CA2575838A1 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US8822223B2 (en) 2004-10-07 2014-09-02 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
EA012162B1 (ru) 2004-10-22 2009-08-28 Эмджен Инк. Способ рефолдинга рекомбинантных антител
EP2500415A1 (de) 2006-09-13 2012-09-19 Abbott Laboratories Verbesserungen an Zellkulturen
CA2910619A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
MY183797A (en) 2006-09-18 2021-03-16 Univ Arkansas Compositions and methods of enhancing immune responses
EP4512422A3 (de) 2007-09-14 2025-05-21 Amgen Inc. Homogene antikörperpopulationen
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
CN101969990B (zh) 2007-11-01 2014-07-09 阿肯色大学评议会 增强针对艾美球虫属的免疫反应的组合物和方法
TWI478937B (zh) 2008-01-15 2015-04-01 Abbvie Inc 改良之哺乳動物表現載體及其用途
ES2642629T3 (es) 2009-11-17 2017-11-17 E. R. Squibb & Sons, L.L.C. Métodos para la producción mejorada de proteínas
NO2525817T3 (de) 2010-01-21 2018-01-06
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
BR112015019283B1 (pt) 2013-02-14 2023-12-19 The Board Of Trustees Of The University Of Arkansas Composições e métodos de aprimoramento de respostas imunes à eiméria ou infecção por eiméria limitadora
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR20180063881A (ko) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
PE20180802A1 (es) 2015-08-05 2018-05-09 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
EP4067493A1 (de) 2016-05-11 2022-10-05 Amgen Inc. Direkte auswahl von zellen, die hohe konzentrationen von heteromeren proteinen exprimieren, mittels intragener komplementierungsvektoren der glutaminsynthetase
AU2018223822A1 (en) * 2017-02-27 2019-07-11 Shattuck Labs, Inc. CSF1R-based chimeric proteins
US11332509B2 (en) 2017-02-27 2022-05-17 Shattuck Labs, Inc. Methods of making and using extracellular domain-based chimeric proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
FI981765L (fi) 1998-08-17
JPH07504083A (ja) 1995-05-11
JPH10150994A (ja) 1998-06-09
CA2312667A1 (en) 1993-04-29
NO941422D0 (no) 1994-04-19
ATE239790T1 (de) 2003-05-15
KR100283541B1 (ko) 2001-03-02
NO980030L (no) 1998-01-05
ES2227513T5 (es) 2009-04-01
DK0822199T3 (da) 2004-12-27
HK1019343A1 (en) 2000-02-03
DE69233402D1 (de) 2004-09-23
DE69233051D1 (de) 2003-06-12
FI941837L (fi) 1994-05-30
NO320073B1 (no) 2005-10-17
CA2121798C (en) 2007-07-24
DE69233402T2 (de) 2005-09-15
FI116850B (fi) 2006-03-15
FI941837A0 (fi) 1994-04-20
AU661360B2 (en) 1995-07-20
CA2312667C (en) 2002-11-19
ES2227513T3 (es) 2005-04-01
ES2198025T3 (es) 2004-01-16
CA2121798A1 (en) 1993-04-29
EP0667901A1 (de) 1995-08-23
NO941422L (de) 1994-06-27
JP3308534B2 (ja) 2002-07-29
EP0897983A3 (de) 1999-03-17
EP0667901B2 (de) 2008-10-15
DK0667901T3 (da) 2004-12-27
NO317625B1 (no) 2004-11-29
WO1993008207A1 (en) 1993-04-29
EP0897983A2 (de) 1999-02-24
EP0667901B1 (de) 2004-08-18
DE69233051T2 (de) 2004-03-11
FI981765A0 (fi) 1998-08-17
NO980030D0 (no) 1998-01-05
EP0667901A4 (de) 1995-06-22
AU3122693A (en) 1993-05-21
ATE274055T1 (de) 2004-09-15
FI116828B (fi) 2006-03-15
JP2877788B2 (ja) 1999-03-31
DK0897983T3 (da) 2003-08-11
DE69233402T3 (de) 2009-06-25
EP0897983B1 (de) 2003-05-07

Similar Documents

Publication Publication Date Title
DK0667901T3 (da) Hidtil ukendt cytokin
DE3773293D1 (de) Weiche intraokulare linse.
FI892020L (fi) Fack foer is och iskuber formade i detta.
DE69009901D1 (de) Lichtleiter.
DE3685004D1 (de) Intraokulare linse.
DE3762798D1 (de) Intraokulare linse mit konvergierenden und divergierenden optischen teilen.
SE8403155L (sv) Sond med instellbart kontaktstift
DE68916079D1 (de) Intraokulare Linse.
DE68929457D1 (de) Fokusverstelleinrichtung
DE68914414D1 (de) Lichtquelle.
DE3850528D1 (de) Intraokulare Linse.
FI894671A0 (fi) Reglerbar faestanordning.
FI912586A0 (fi) Adipsin och komplement d aktiviteter innehaollande kombinationsproteiner.
DE68924077D1 (de) Optisches Gerät mit Laser.
DE69007332D1 (de) Optische Verstärkungseinrichtung mit niedrigem Rauschen.
DE69008220D1 (de) Lichtleiter-Beschichtungssteuerung.
DE3780254D1 (de) Ringlaserkreisel mit geometrisch induziertem "bias".
DE68909704D1 (de) Optischer Verstärker mit reduzierter Nichtlinearität.
DK188689D0 (da) Linse
DE3768771D1 (de) Faltbare intraokulare linse.
ATE98761T1 (de) Laermisolierung mit lichtreflektierender oberflaeche.
ES1006699Y (es) Quemador protesico orientable.
NO910287D0 (no) Flerfokal intraokulaer linse.
NO882944D0 (no) Intraokulaer linse med justerbar styrke.
DE69128032D1 (de) Automatische Einstellung der optischen Ausgangsleistung von mehreren optischen Sendern